Health ❯ Healthcare ❯ Medical Research ❯ Oncology

Lung Cancer

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

The company is advancing toward a pre‑NDA meeting with the FDA following the launch of a global Phase 3 trial against alectinib.

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Preclinical Candidate AVJ16 Blocks IGF2BP1 to Halt Lung Tumor Growth in Models

EML4-ALK V3 Proves More Aggressive and Less Drug-Sensitive Than V1 in New Study

IFITM3 Identified as Key Modulator of Immunotherapy Response in Small Cell Lung Cancer

Early ctDNA Test Flags Which LS-SCLC Patients Benefit From Consolidation Immunotherapy

3-Week Radiotherapy Regimen Matches Survival, Cuts Severe Toxicity in Limited-Stage SCLC Trial

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

Comprehensive NGS Study Unveils Diverse Mutational Landscape in Lung Squamous Cell Carcinoma

AI Model Sybil Validated for Lung Cancer Risk Prediction in Diverse Populations